

Pharmacokinetics and toxicity challenges to delivery of cancer nano-medicines

Rakesh Dixit

Bionavigen, USA



Abstract

Nanomedicines are increasingly being used to diagnose, prevent and treat human diseases. Nanotechnological advances are enabling targeted delivery of difficult to deliver innovative therapies, including gene editing and disease correcting gene delivery, highly lipophilic cytotoxic cancer drugs, mod RNA, etc. Although nanomedicines offer great opportunities for targeted delivery, they have increasingly faced safety, disposition, CMC and manufacturing challenges that have limited their utility. With special emphasis on safety and pharmacokinetics, the presentation will discuss the safety, pharmacokinetics, CMC and other challenges in the development of nanomedicines with emphasis cancer therapeutic nanomedicines.

Biography

Rakesh Dixit conducted extensive undergraduate, graduate and post-graduate training in Toxicology-Biochemistry with both Indian and US Institutions (Case Western Reserve University, Medical College of Ohio, University of Nebraska) and is board certified in Toxicology from the American Board of Toxicology Inc. since 1992.

[International Conference on Pharmaceutics and Advanced Drug Delivery Systems](#) | Rome, Italy | February 24-25, 2020

Citation: Rakesh Dixit, *Pharmacokinetics and toxicity challenges to delivery of cancer nano-medicines*, Global Pharma Congress 2020, International Conference on Pharmaceutics and Advanced Drug Delivery Systems, Rome, Italy, February 24-25, 2020, Page 05